BridgeMD
Tests treatment safety and results for Relapsed or Resistant Acute Leukaemias
Official title The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
ClinicalTrials.gov ID: NCT05756322
What this study is testing
What is LBS-007?
LBS-007 is an investigational medicine, being studied as a potential treatment for relapsed or resistant acute leukaemias.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 120
You may be able to join if
- Male or female people greater than 18 years old, inclusive.
- Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.
- Patients who are ineligible for standard therapies that are anticipated to result in durable remission or cure, or who have no known therapy options...
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
You likely can't join if
- Concomitant chemotherapy, radiation therapy, or immunotherapy.
- Receiving any other investigational agents concurrently or within 30 days prior to screening.
- Patient has acute promyelocytic leukaemia or leukemia with active CNS involvement.
- History of another active malignancy with 2 years prior to study entry, basal cell skin cancer and previous carcinoma in treated curatively.
- Patient with mental deficits and/or psychiatric history that precludes them from giving informed consent or from following protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Tampa, Florida, United States
- Chicago, Illinois, United States
- Fairway, Kansas, United States
- Baltimore, Maryland, United States
- Chapel Hill, North Carolina, United States
- Wollongong, New South Wales, Australia
- Benowa, Queensland, Australia
- Adelaide, South Australia, Australia
- Melbourne, Victoria, Australia
- Nedlands, Washington, Australia
- Perth, Washington, Australia
- Xinxiang, Henan, China
- Jining, Shandong, China
- Tianjin, China
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 120 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tampa, Florida, United States; Chicago, Illinois, United States; Fairway, Kansas, United States; Baltimore, Maryland, United States; Chapel Hill, North Carolina, United States; Wollongong, New South Wales, Australia and 11 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.